缉毒署主任Anne Milgram面临对机构失职的批评,包括未解决的卡特尔和大麻研究积压。 DEA chief Anne Milgram faces criticism over agency failures, including unaddressed cartels and a cannabis research backlog.

毒品管制署署长Anne Milgram承诺在2021年进行数据驱动的改革,他面临机构功能失调的批评,包括未能打击中国资助的卡特尔和长达十年的阻碍大麻研究的许可证积压。 DEA Administrator Anne Milgram, who promised data-driven reform in 2021, faced criticism for agency dysfunction, including a failure to combat Chinese-financed cartels and a decade-long licensing backlog that hindered cannabis research. 内部做法被指控偏袒内部人,无视数据,把合法制药公司作为国际犯罪网络的目标。 Internal practices were accused of favoring insiders, ignoring data, and targeting legal pharmaceutical companies over international criminal networks. 包括Thomas Prevoznik和Matthew海峡等官员都受到严格审查,而Milgram的监管在道德关切和法律挑战中受到质疑。 Officials including Thomas Prevoznik and Matthew Strait drew scrutiny, while Milgram’s oversight came under question amid ethical concerns and legal challenges.